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Background: A subset of hereditary cerebellar ataxias is inherited as autosomal recessive traits (ARCAs).
Classification of recessive ataxias due to phenotypic differences in the cerebellum and cerebellar structures is
constantly evolving due to new identified disease genes. Recently, reports have linked mutations in genes involved
in ubiquitination (RNF216, OTUD4, STUB1) to ARCA with hypogonadism.
Methods and results: With a combination of homozygozity mapping and exome sequencing, we identified three
mutations in STUB1 in two families with ARCA and cognitive impairment; a homozygous missense variant (c.194A > G,
p.Asn65Ser) that segregated in three affected siblings, and a missense change (c.82G > A, p.Glu28Lys) which was
inherited in trans with a nonsense mutation (c.430A > T, p.Lys144Ter) in another patient. STUB1 encodes CHIP
(C-terminus of Heat shock protein 70 – Interacting Protein), a dual function protein with a role in ubiquitination as a
co-chaperone with heat shock proteins, and as an E3 ligase. We show that the p.Asn65Ser substitution impairs CHIP’s
ability to ubiquitinate HSC70 in vitro, despite being able to self-ubiquitinate. These results are consistent with previous
studies highlighting this as a critical residue for the interaction between CHIP and its co-chaperones. Furthermore, we
show that the levels of CHIP are strongly reduced in vivo in patients’ fibroblasts compared to controls.
Conclusions: These results suggest that STUB1 mutations might cause disease by impacting not only the E3 ligase
function, but also its protein interaction properties and protein amount. Whether the clinical heterogeneity seen in
STUB1 ARCA can be related to the location of the mutations remains to be understood, but interestingly, all siblings
with the p.Asn65Ser substitution showed a marked appearance of accelerated aging not previously described in STUB1
related ARCA, none display hormonal aberrations/clinical hypogonadism while some affected family members had
diabetes, alopecia, uveitis and ulcerative colitis, further refining the spectrum of STUB1 related disease.
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Autosomal recessive hereditary cerebellar ataxias (ARCA)
include a large number of rare degenerative disorders
where gait disorder or clumsiness present as a key feature
from an early age (characteristically before 20 years) [1].
Mutations in more than 20 genes have been found causal
in these diseases. Despite the progress in gene identification,* Correspondence: kheimdal@ous-hf.no
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unless otherwise stated.the molecular cause of disease still remains to be identified
in about 40% of the families [1]. ARCAs are commonly
classified according to mode of transmission and presence
of additional features. In many cases, neurodegeneration
with motor and cognitive deterioration are present in
addition to ataxia.
Gordon Holmes syndrome (MIM 212840, hereditary
cerebellar ataxia with hypogonadism) is one of these rare
autosomal recessive syndromes combining ARCA with
extracerebellar syndromes (hypogonadotrophic hypogonad-
ism and often progressive dementia). Recently, Margolinl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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alone or in combination with mutations in OTUD4 as
cause for this disease [2]. Interestingly, both genes encode
enzymes in the ubiquitin pathway linking Gordon Holmes
syndrome to disordered ubiquitation. Dysregulation of ubi-
quitination has also been linked to major neurodegenera-
tive diseases such as Alzheimer and Parkinson [3,4]. These
diseases have been associated with an accumulation of ab-
normal (misfolded) protein either as intracellular inclusions
and/or in the extracellular space e.g. as amyloid depositis.
The discovery of such excessive protein deposits, which in
a normal state would be targeted to elimination by the cell
defense (proteasome) system, has pointed to common
mechanisms as cause for such general neurodegenerative
diseases.
In 2013, Shi et al. reported, by exome sequencing, that
mutations in the STUB1 gene are a novel cause for Gordon
Holmes syndrome [5]. The STUB1 gene (STIP1 homology
and U-box containing protein 1, E3 ubiquitin protein lig-
ase) encodes CHIP, which is an E3 ubiquitin protein ligase.
The role of ubiquitin ligases is to recognize the target pro-
tein to be ubiquitinated and mediate the attachment of
ubiquitin. One affected sibling pair had a homozygous mu-
tation predicted to lead to a missense change in the C-
terminus of CHIP. The functional effect of the mutation
was reported as reduced ubiquitin ligase activity. In an-
other study, five additional STUB1 mutations were re-
ported in three different families [6]. All mutations were
found to affect the ability of CHIP to promote N-methyl-
D-aspartate receptor subunit degradation in vitro, which
was suggested to be the underlying mechanism for the
development of ARCA in these patients. Although all
three Gordon Holmes associated genes (RNF216, OTUD4,
STUB1) play a role in the ubiquitin system, the presence of
dementia and white matter lesions on MRI has so far only
been observed with RNF216/OTUD4 mutations, illustrat-
ing some phenotypic diversity related to this syndrome [2].
Moreover, two groups recently reported additional families
with ARCA due to STUB1 mutations [7,8], further describ-
ing the heterogeneity of the syndrome.
CHIP is short for C-terminus of HSC70-interacting pro-
tein, thus it interacts with heat shock proteins (HSPs) that
are highly conserved and abundantly expressed chaperone
proteins with diverse functions. The most studied of these
interacting proteins are HSC70, HSP70 and HSP90 [9].
CHIP functions both as a co-chaperone and an E3-
ubiquitin ligase that couples protein folding and prote-
asome mediated degradation by interacting with heat
shock proteins (e.g. HSC70) and ubiquitinating their mis-
folded client proteins thereby targeting them for proteaso-
mal degradation (Figure 1).
CHIP itself comprises three functional domains: Tetra-
tricopeptide repeat (TPR) domain, coiled-coil (CC) and U-
box domain. The N-terminal TPR domain is the bindingsite for a wide range of proteins to be ubiquitinated by
CHIP, including the HSPs (Figure 1). So far, more than 30
proteins have been identified as targets of CHIP [10]. The
list includes ataxin-1, a protein that causes spinocerebellar
ataxia type-1 (SCA1) when harboring an expansion of a
polyglutamine tract [11]. CHIP has been found to be im-
portant for cellular differentiation and survival (apoptosis),
and response to stress [10]. Further, studies in cell culture
and post-mortem neurons have demonstrated a direct
interaction between CHIP and ataxin-1, providing a link
between CHIP and cerebellar ataxias [11]. Mouse models
also support that CHIP may be important in preventing
neurodegenerative diseases due to accumulation of abnor-
mal proteins such as huntingtin or ataxin-3, and that hap-
loinsufficiency of CHIP may accelerate such diseases
[12,13]. Mice deficient in CHIP develop normally, but die
prematurely with significant mortality observed in the
peripartum and early postnatal periods. They demonstrate
signs of specific behavioural impairments [10], and accel-
erated ageing, which is accompanied by signs of deranged
protein quality control [14,15].
We investigated a consanguineous family with ARCA.
Two affected brothers and their sister were found to
share a homozygous missense variant in the tetratrico-
peptide domain of STUB1 encoded CHIP. The variant
was identified by homozygosity mapping using SNP-
arrays followed by exome sequencing analysing genes in
the homozygous region. To our knowledge, this is the
third family with a mutation located in the TPR domain
of CHIP. From our cohort of patients with ataxia, an
additional patient with progressive ataxia and secondary
infertility was selected for analysis, based on the pheno-
type similarities with the first family. Sanger sequencing
demonstrated that this patient was compound heterozy-
gous for a missense and a nonsense mutation in STUB1.
The effect of the mutations on CHIP function was inves-
tigated by measuring CHIP ubiquitin ligase activity,
using HSC70 as substrate for ubiquitination, as well as




Two affected brothers and their sister (Family 1) all pre-
sented with increasing gait disturbances and cognitive
regression from 6 years of age, in addition to other non–
neurological symptoms (Table 1). The parents are related
(first cousins) of Arabic heritage originally from the
Middle East, but living in Norway since the mid 1980’ies.
The family is consanguineous and 7/8 grandparents des-
cend from the same family. The affected siblings are pres-
ently 20–30 years old. Puberty/sexual developments have
been un-remarkable, however menarche was somewhat de-
layed in the sister compared to other females in the family.
Figure 1 The dual role of CHIP as both a co-chaperone and an E3 ligase targeting misfolded proteins to proteasome degradation.
CHIP binds to HSC70 by its TPR domain and bridges HSC70 to the misfolded protein. An E2 enzyme binds to the U-box domain and CHIP
catalyses the ubiquitination reaction by attaching ubiquitin to the HSC70-client protein, targeting it to the proteasome. HSC70 and CHIP are also
ubiquitinated, however this is not a signal for proteasomal degradation, but might play a role in their self-regulation.
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patient with secondary infertility due to hypogonado-
trophic hypogonadism, in addition to ataxia. She was in-
cluded in the study due to phenotypic similarity with the
patients described in the first publication by Shi et al.
[5]. The patient originates from Sri Lanka. Her parents
are unrelated but from the same geographical area. She
was completely healthy until the age of 25, when she de-
veloped secondary infertility. The first signs of ataxia
started at age 33.
Informed written consent was obtained from all partici-
pants. The study was approved by the Regional Committee
for Medical and Research Ethics, South East Norway (ref.
no. 2012/1425b), and adhered to the tenets of the Declar-
ation of Helsinki.
Genotyping and sequencing
Genome wide SNP genotyping was performed with the
Genome Wide Human SNP array 6.0 (Affymetrix, Santa
Clara). Whole genome homozygozity mapping was per-
formed using PLINK v1.07 [16,17] searching for any re-
gion >2 Mb, with minimum of 30 SNPs and less than four
heterozygous calls. Whole exome capture and paired-end
100 nt sequencing was performed at HudsonAlpha Insti-
tute for Biotechnology (Huntsville,AL) as described in
(Haugarvoll 2013). The 8.7 Giga-bases of aligned sequence
data resulted in 55X median coverage of the target capture
regions, with more than 96% of target bases covered a
minimum of 8X. PCR duplicates were removed with
PICARD (http://broadinstitute.github.io/picard/) and the
Genome analysis toolkit [18] was used for base quality re-
calibration and variant calling using a minimum threshold
of 8X sequencing depth and quality score ≤ 30. Annovar
[19] was used for variant annotation. Variant prioritizationwas performed as described in [20] based on an autosomal
recessive model, filtering against variants identified in
more than 100 Norwegian exome-resequencing samples
(obtained using the same whole exome sequencing pipe-
line) and variants present at >0.5% allele frequency in the
1000 Genomes database. Variants were verified by Sanger
sequencing using the BigDye terminator kit and the
ABI7900 Genetic Analyzer. For the proband in Family 2,
all exons and intron/exon boundaries in STUB1 were
sequenced by Sanger sequencing (primers and conditions
available upon request). To test whether the mutations
found in Patient 2 were located on different strands we
used the TOPO® TA Cloning® Kit (Invitrogen, Life technolo-
gies, 11329-H07E-25, California) to clone PCR-products
spanning both mutations, followed by Sanger sequencing
of the clones. STUB1 reference sequence (RefSeq) used:
NM_005861.2
RNA-studies
Total RNA was purified from blood using the Tempus
system (Life Technologies, California) or from cultured
fibroblasts using the RNEasy-kit (Qiagen, Germany).
Reverse transcription and cDNA synthesis were per-
formed using the SuperScript® VILO™ cDNA Synthesis Kit
(Life Technologies, California). Expression of the STUB1
gene was measured by qPCR using MGB-probes (Life
Technologies, California) and gene expression was
normalized using beta-actin and GADPH as endogenous
controls. Relative expression was calculated using the
delta Ct- method.
Plasmids and constructs
The full length cDNA encoding CHIP from purchased
vector pMXs.EXBi-STUB1-IRES-Puro (Cyagen Bioscience




P1[II-1], male, 26 P1[II-2], male, 30 P1[II-3], female, 20 P2, female, 45
Substitution N65S/N65S N65S/N65S N65S/N65S E28K/K144*
Age of onset 2 years CP diagnosis at birth 8 months 33 years





Aged appearance Aged appearance Aged appearance None
Long slender fingers, increased
space between digits four and
five, adducted thumbs



















Cerebellar ataxia (17), dysarthria
Cognitive impairment
Epilepsy until 2 years of
age
Cerebellar ataxia, dysarthria, dysphagia Decreased tempo




Cognitive impairmentIncreased muscle tone (rigidity)
Cognitive impairment




posterior corpus callosum, mild
thinning of pons
Severe cerebellar atrophy, thin corpus
callosum, thin pons
Cerebellar hypoplasia, thin
pons and corpus callosum
Cerebellar hypoplasia,




Horizontal nystagmus Left sided chronic iridocyclitis with
secundary glaucoma; Oculomotor










Other Alopecia Ulcerative colitis Slight presbyacusis Pancreatitis
Slight presbyacusis
*Disability score → 0: no functional handicap; 1: no functional handicap but signs at examination; 2: mild, able to run, walking unlimited; 3: moderate, unable to
run, limited walking without aid; 4: severe, walking with one stick; 5: walking with two sticks; 6: unable to walk, requiring wheelchair; 7: confined to bed.
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vector pETM-41 (EMBL, Heidelberg, Germany), and
the mammalian expression vector pcDNA3.1/V5-HisB
(Invitrogen, California). Resulting constructs pETM-41-
CHIP and pcDNA3.1V5-HisB-CHIP were used as
templates for site directed mutagenesis (Quick change
kit, Stratagene, California) generating plasmids contain-
ing the following CHIP point mutations (E28K), (N65S),
(K144*) and (T246M). The authenticity of each
construct was confirmed by DNA sequencing.Protein expression and purification
Hisx6-MBP-tagged CHIP, wild type and mutant recom-
binant protein, were expressed in BL21-CodonPlus
(DE3)-RP Competent Cells (Agilent, California). Briefly,
transformed cells were grown in LB medium added 0.2%
glucose until A600 reached 0.6, and induced with 0.5
mM isopropyl-β- D-thiogalactopyranoside for 5 hours at
30°C. Cells were harvested and lysed by sonication. The
Hisx6-MBP-tagged proteins were purified using Amylose
resin (New England Biolabs, Massachussets), according
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the Hisx6-MBP-tagged fusion proteins were cleaved by to-
bacco etch virus protease (TEV) for 2 hours at room
temperature.
Expression of CHIP proteins by the in vitro coupled
transcription/translation system
CHIP-WT and CHIP-N65S were expressed in vitro in a
coupled transcription/translation system (TNT T7 Quick-
coupled Transcription/Translation system; Promega) using
2 μg plasmid DNA and in the presence of [35S]Met (10
μCi), 20 mM DTT and 40 μl of rabbit reticulocyte lysate.
Expression was performed at 30°C for 90 min, and samples
analyzed by SDS-PAGE and autoradiography.
In vitro ubiquitination assay
In vitro ubiquitination reactions were set up as previ-
ously described [5]. Ubiquitination immediately followed
after production of recombinant MBP-CHIP forms, and
after cleaving 2 h at room temperature with 1 μg of TEV
per 10 μg of protein, if tag-free CHIP was used in the
analyses. In a total volume of 20 μl of 50 mM Tris HCl
(pH 7.5), 0.6 mM DTT and 2.5 mM Mg-ATP (Sigma
Aldrich, Missouri), 2.5 μM of recombinant CHIP was in-
cubated with 50 nM Ube1 (Boston Biochem, E-305,
Massachussets), 2.5 μM UbcH5c (Boston Biochem, E2-
627, Massachussets), 0.7 μM HSC70 (SinoBiological Life
technologies, 11329-H07E-25, California), and 250 μM
ubiquitin (BostonBiochem, U-100H, Massachussets), for
1 h at 37°C. Samples were analyzed by SDS-PAGE (4-
12%) and immunoblotting using anti-HSC70 (Enzo,
ADI-SPA-815, New York) or anti-CHIP (LifeSpan Bio-
sciences, LS-C137950, Washington) antibodies.
Fibroblast culture
Four millimeter punch biopsies were obtained from the
skin of the ventral aspect of the forearm of patients P2,
P1 and the father of P1 (F-P1) in local anesthesia and
shipped to the laboratory in transport medium. The skin
biopsies were cultured and expanded in Amniochrome
II Basal medium with Amniochrome II Modified Supple-
ment (Lonza) at 37°C in 5% Co2. High confluent cells
were washed with PBS and harvested in RIPA Buffer
with 1X Halt Protease Inhibitor Cocktail, and analyzed
by SDS-PAGE (10%) and immunoblotting using anti-




All clinical features are summarized in Table 1.
Family 1: There is adult onset diabetes in several
members on the paternal side, including the father, but
no other instances of ataxia or mental impairment in thefamily. Several family members including patient P1
[II-1] have thalassemia minor. All siblings were born
after uneventful pregnancies except the youngest who
was born prematurely.
The index case (Patient P1[II-1]) is a 26 year old male
who was considered normal from birth until his grand-
mother remarked delayed development (motor and cog-
nitive) when the boy was 2 years old. He started walking
independently at age 2 ½. He has always had an un-
steady gait with progression of ataxia particularly from
the early teens. Motor function was reasonable until
about 7 years of age (he could use a bicycle, play soccer
and run, but slower than other children). Presently, he
can walk independently for short distances, but prefers
using a walker. The family moved to Norway when he
was 6 years old and he has learnt a little Norwegian. Re-
cently, he has had increasing difficulties with expressive
language. He did not attend regular school and has
never learned to read or write. He experienced normal
pubertal development and physical appearance. External
genitals are normal for an adult male. He developed dia-
betes type I from age 16. His hair was normal until 4–5
years of age after which he developed near total alopecia,
which was treated with systemic steroids with little clin-
ical effect. He has no dysmorphic features, but his phys-
ical appearance resembles that of a much older person
than his chronological age of 26 years.
Endocrine investigations at age 26 shows normal pituit-
ary (marginally raised prolactin), testosterone (SHBG at
upper reference limit for laboratory), and adrenal function.
Anti-TPO was increased to six times the upper limit of
normal (ULN), however with clinical and biochemical nor-
mal thyroid function, and no goitre. Other endocrine
autoantibodies were normal. Pure tone audiometry indi-
cated very mild sensorineural hearing loss in the high fre-
quencies from 4000 Hz, as seen in presbyacusis or after
noise exposure. Cardiac examination including echocardi-
ography, and bone mineral measurements were normal.
Cerebral MRI showed severe cerebellar atrophy, atrophy
of the corpus callosum particularly pronounced anteriorly,
and a slight atrophy of the pons and brainstem (Figure 2A
and B).
The elder brother (P1[II-2]), now 30 years of age, has
a similar clinical picture as the index case, however, his
neurological condition appears more severe. He is still
ambulatory with a walking chair and communicates ver-
bally. He was initially diagnosed with cerebral paresis in
his native country. He developed therapy resistant ul-
cerative colitis at age 22 treated with proctocolectomy.
Asymptomatic uveitis developed in his left eye 26 years
old. There has been marked neurological progression
with worsening ataxia and a decline in higher mental
functions. The parents informed us that he had a normal
pubertal development and he has the appearance of a
A B
Figure 2 Cerebral MRI (1.5 Tesla). (A) Cerebral MRI (T1 serie, midline sagittal) of the proband in Family 1 at the time of investigation. Severe
atrophy of the whole cerebellum and the anterior part of the corpus callosum. (B) Same examination, but T2 axial scan at the level of the
superior cerebellar peduncle. There is an atrophy of both cerebellar hemispheres with widened sulci, and vermis atrophy. The fourth ventricle is
moderately dilated. There are a few diffuse hyperintensity signals in the brainstem. The cerebral hemispheres look normal.
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his biological age. He has refused further clinical and
supplementary investigations at this point.
The younger sister (P1[II-3]), now 18 years of age, has
a similar clinical picture albeit milder than her brothers.
She was born prematurely and had epilepsy (generalized)
8 months old. She was medicated until 2 ½ years of age
and has not had seizures since. She has ataxia and im-
paired cognition, but has learnt to write her name in
school and is able to read a few words. The parents were
certain she had the same condition as her brothers when
she was eight months old. She walked independently at
age 2 ½. Motor development has been slow. She devel-
oped cerebellar ataxia with increasing gait impairment
from age 15, but is still ambulatory without walking aids,
and has very moderate extremities’ ataxia. She can walk, but
is unable to run. She speaks Arabic and some Norwegian,
does not know how to add but can count.
Sexual development has been normal with menarche at
age 15 followed by regular periods. Physical appearance is
that of a normal female with very slight and unspecific
dysmorphic features, however, with a much more aged ap-
pearance than expected for an 18 year old woman. Endo-
crine investigations at age 18 shows normal pituitary
function, normal sex hormones and adrenal function. We
found no indications of autoimmune endocrinopathies.
Pure tone audiometry indicated very mild sensorineural
hearing loss in the high frequencies comparable to that
found in her brother. Cardiac examination including echo-
cardiography and bone mineral measurements were
normal.
Patient P2 is a 45 year old woman of Sri Lankan descent
living in Norway. She is the youngest of three children of
unrelated healthy parents and the only affected family
member. She developed ataxia after the age of 30, but her
primary symptoms presented as secondary infertility dueto hypogonadotrophic hypogonadism. Development was
normal during childhood and adolescence. She had nor-
mal sexual development with menarche 14 years old and
childbirth 25 years old. After giving birth, she has had oli-
gomenorrhea and secondary infertility. Investigations
showed deficits in pituitary function and “empty sella” on
MRI. Neurological symptoms started at about age 32 with
increasing difficulties with walking and ataxia. The condi-
tion has been slowly progressive. She is still ambulatory,
but needs the support of a walker due to impaired
balance.
Whole genome genotyping and exome sequencing
identify a homozygous STUB1 mutation segregating with
ARCA in Family 1
The consanguineous structure of Family 1 suggested
recessive inheritance and we therefore performed whole
genome genotyping to search for regions of homozygosity
in the three affected siblings and their parents. We identi-
fied two regions of homozygosity shared identity by des-
cent among the three affected siblings: a 6.6 Mb area on
chromosome 5 (25,455,664-32,08505, NCBI Build 36.3)
and 2.7 Mb region on chromosome 16 (0–2,764,985).
None of the areas contained known ARCA genes or other
obvious candidate genes. We next performed whole ex-
ome sequencing in the index patient (Additional file 1:
Table S1). This identified 20438 genetic variants of which
429 were non-synonymous and not found in 100 Norwe-
gian exomes or in the 1000 Genomes database at > 0.5%
allele frequency. Only one variant, c.194A >G in STUB1
was located in a region shared identical by descent in all
three siblings and heterozygous in each parent. Sanger se-
quencing confirmed that the mutation is homozygous in
all three siblings and heterozygous in both parents. The
c.194A >G mutation is located in STUB1 exon 2 and is
predicted to cause an Asparagine (N) to Serine (S) amino
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highly conserved residue. The mutation is predicted as
deleterious by SIFT, Poly-Phen 2 and Mutation Taster and
is not found in 1000G or dbSNP.
Identification of compound heterozygous STUB1
mutations in Family 2
Sanger sequencing of the proband in Family 2 identified
two heterozygous, previously undescribed variants, in
STUB1; c.82G >A and c.430A > T. The c.82G >A muta-
tion is predicted to encode a Glycine to Lysine substitu-
tion at residue 28 (p.Glu28Lys) while the second mutation
results in a premature stop codon, p.Lys144Ter in exon 3.
The mutations were confirmed to be located on different
strands by sequencing of clones derived from PCR-
products spanning both mutations.
Location of the CHIP mutations p.Asn65Ser (observed in
Family 1), p.Glu28Lys, and the truncated form p.Lys144Ter
(both observed in Family 2)
The p.Asn65Ser (CHIP-N65S) and p.Glu28Lys (CHIP-
E28K) mutations are located in the TPR domain important
for chaperone interactions (Figure 3). The Asn-residue at
position 65 is highly conserved (from human to C. elegans)
and previously shown to be directly involved in binding of
substrates such as Smad1, HSC70, HSP70 and HSP90 [21].
The non-synonymous heterozygous change in Family 2
alters a glutamic acid (E) to lysine (K) in position 28, close
to a second critical residue for substrate binding (Lys30) in
the TPR domain [21], and predicts a change from a
negatively to a positively charged amino acid. The second
mutation seen in patient 2 is predicted to lead to a prema-
ture stop codon (CHIP-K144*) and may result in loss of
translation into a functional protein. Just recently, Shi and
colleagues reported one family with another homozygous
STUB1 mutation as the cause of ataxia and hypogonadism
in two siblings of a consanguineous marriage [5]. Interest-











Figure 3 Functional domains of the CHIP protein and illustration of am
CHIP E3-Ligase with its three functional domains: Tetratricopeptide repeat (TP
point mutation resulting in CHIP-N65S located in the TPR domain. Patient 2 (P
CHIP-E28K in the TPR domain and another causing the deletion mutant CHIP
U-box domain. The mutation resulting in the CHIP-T246M mutant is located i
here in Patient 3 (P3).domain (Figure 3) and is thus more likely to directly impair
the ubiquitin ligase activity, while retaining normal sub-
strate binding of CHIP. We decided to include this mutant
in our functional studies for comparison.Decreased levels of steady-state CHIP observed in patient
fibroblasts
Immunoblot analysis using a CHIP specific antibody
shows that fibroblasts derived from Patients 1 (P1[II-1])
and 2 (P2) have much lower steady state levels of CHIP
protein compared to both normal fibroblasts and the
healthy father of Patient 1 (P1[I-1], Figure 4). In the
compound heterozygous Patient 2, only a weak band cor-
responding to CHIP-E28K is detected. No lower molecu-
lar weight form corresponding to an estimated ~16 kDa
CHIP-K144* truncated form could be detected, suggesting
that CHIP-K144* is not present as a mature protein in the
patient. This was later confirmed by quantitative RT-PCR
(data not shown). For Patient 1 P1[II-1] the band corre-
sponding to CHIP-N65S migrates slightly faster during
SDS-PAGE compared to the CHIP-WT band (Figure 4).
Similarly, in fibroblasts from the heterozygous carrier of
the N65S mutant allele (P1[I-1]), a double band with
different migration pattern can be observed (CHIP-WT
and CHIP-N65S). This migration difference for CHIP-
N65S is probably due to a protein conformational change
induced by the mutation, as we observe the same slight
migration difference for CHIP-N65S when it is i)
expressed in an in vitro rabbit reticulocyte protein expres-
sion system, ii) expressed in HEK293 cells transfected with
CHIP-N65S encoding plasmids, and also when iii)
expressed in E. coli as recombinant CHIP-N65S (Figure 5).
Since the migration difference is also observed for E. coli
expressed and purified proteins, it is unlikely that the shift
is caused by a post-translational modification, but rather
due to conformational change induced by this particular










ino acid substitutions/deletions found in patients. Presentation of the
R), coiled-coil (CC) and U-box. Patient 1 (P1[II-1]) is homozygous for a
2) is compound heterozygous for two point mutations; one resulting in
-K144*, a truncated protein lacking most of the CC domain and the entire























Figure 4 Differential levels of CHIP protein in fibroblasts from
patients. Fibroblasts from Patient 1 (P1[II-1]) and Patient 2 (P2) show
lower steady-state levels of CHIP protein compared with normal
fibroblasts (WT), as analyzed by SDS-PAGE and immunoblotting using
CHIP-specific antibody. In addition, the band corresponding to
CHIP-N65S mutant in P1 reveals slightly faster migration rate on
SDS-PAGE compared to the CHIP-WT band, probably due to protein
conformational changes induced by the mutation. In fibroblasts from
the father of Patient 1 (P1[I-1]), a heterozygous carrier of the N65S
mutant allele, a double band can be observed (CHIP-WT and CHIP-
N65S). In P2 a weak band most likely corresponding to CHIP-E28K is
detected, while the band corresponding to the lower molecular weight
CHIP-K144* form of ~16 kDa is not observed on this blot. Actin-specific
protein bands are shown to compare the relative amounts of total
protein loaded per lane.
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at the transcript level, we sequenced cDNA derived both
from peripheral blood and cultured fibroblasts from
Patient 1, his heterozygous father and Patient 2. The non-
synonymous mutations were all detected, but no trace of
the CHIP-K144* could be found. Quantitative RT-PCR
showed normal levels (compared to WT) in both the
heterozygous and homozygous carriers in Family 1, and ap-
proximately 50% lower level in the compound heterozygous
Patient 1 (data not shown). These results suggest that the
CHIP-K144* mutant allele is degraded at the transcript
level, possibly due to nonsense mediated decay.
CHIP-N65S demonstrates reduced ubiquitin ligase activity
To study whether the mutations affect substrate binding
and ubiquitin ligase activity, we expressed and purifiedCHIP-WT, CHIP-E28K, CHIP-N65S, CHIP-K144* and
CHIP-T246M, both as recombinant MBP-fusion proteins
and tag-free (cleaved) CHIP. The in vitro ubiquitination
activity of each mutant was assessed using HSC70 recom-
binant protein as substrate. As can be seen in Figure 6 (top
panel), CHIP-K144* and CHIP-T246M fail to ubiquitinate
HSC70 in vitro, while CHIP-E28K is able to ubiquitinate
HSC70 at the same level as CHIP-WT. Interestingly, the
ability of CHIP-N65S to ubiquitinate HSC70 appears
significantly impaired (top panel). To investigate whether
this was due to a defect in binding to HSC70, and not due
to a defect in ubiquitin ligase activity, we also measured the
intrinsic autoubiquitination ability of each of the CHIP
mutants (Figure 6, lower panel). As previously described by
others [5], CHIP-T246M has no ubiquitin ligase activity
and showed no autoubiquitination. In contrast, both
mutants with affected TPR domain (lower panel) showed
levels of autoubiquitination indistinguishable from the WT
protein and thus, appear to have intact ability to ubiquiti-
nate. Therefore, low substrate affinity is the more likely
mechanism for the reduced HSC70 ubiquitination observed
for CHIP-N65S. The lower molecular weight K144*
deletion mutant was detected as a MBP fusion protein, but
not as a tag-free mutant, presumably due to reduced
protein stability after removal of the MBP.
Discussion
We used a combination of homozygosity mapping and
exome sequencing to identify the disease causing DNA
variant in a consanguineous family with cerebellar ataxia.
During the course of our investigations, four research
groups reported STUB1 mutations as the disease cause in
families with ARCA with/without hormonal aberrations
and auxilliary clinical findings [5,6,8,22]. We followed up
on this by identifying another mutation in STUB1 in the
only family we have registered in our local database,
presenting with a combination of ataxia and hypogonado-
trophic hypogonadism, as well as additional symptoms
possibly related to disease. As such, our data support the
observation that mild to moderate and usually progressive
cognitive impairment, is part of the clinical picture in
STUB1-related ARCA. Importantly, despite their earlier
onset of ataxia and more pronounced cognitive impair-
ment, so far the patients in Family 1 have not experienced
hormonal derangements as reported in some, but not all
previously investigated families. This suggests that hypo-
gonadotrophic hypogonadism may not be an obligatory
feature of STUB1-related disease. We did not register
pyramidal signs in our patients, in contrast to the observa-
tions of Synofzyk et al. [7]. However, they only found
direct clinical evidence for pyramidal involvement in one
family, and reported indirect pyramidal involvement in
the other two, using central motor conduction time study.













































































Figure 5 CHIP-N65S causes a migration shift when analyzed by SDS-PAGE. (A) CHIP-WT and CHIP-N65S were translated in a TNT coupled
transcription/translation system in the presence of [35S]Met, as described in Material & Methods. Samples were analyzed by SDS-PAGE and
autoradiography. A double band can be observed for CHIP-WT, in which the lower band migrates at the same rate as CHIP-N65S. CTL; empty
vector as negative control. (B) CHIP expression of transfected HEK293 cells with CHIP-WT or CHIP-N65S, tagged with V5 and His, and detected by
SDS-PAGE and immunoblotting using anti-CHIP. Endogenous CHIP is observed at 35 kDa. The shift is observed only for transfected CHIP.
A secondary isoform of CHIP appears at 32 kDa, lacking the first 72 amino acids, only observed in vitro [9]. CTL; empty vector as negative control.
(C) Recombinant WT and CHIP variants expressed and purified from E. coli as MBP-fusion proteins and cleaved by TEV protease as described in
Materials & Methods. Samples were analyzed by SDS-PAGE and coomassie staining. The migration shift is only observed for CHIP-N65S.
CHIP-K144* appears at a lower molecular weight (truncated version of 16 kDa).
Heimdal et al. Orphanet Journal of Rare Diseases 2014, 9:146 Page 9 of 12
http://www.ojrd.com/content/9/1/146the lack of clinical suspicion. Pyramidal signs were not
reported in the other studies [5,8]. The main findings of
our MRI analyses were severe cerebellar atrophy, as
reported by previous studies with STUB1 mutations, and
in addition a distinct thinning of the anterior part of the
corpus callosum (CC), not reported previously (Figure 2).
Thin CC appears to be a common feature of many ARCAs
[1]. Whether the thinning is a progressive feature, or
whether it is associated with specific mutations, remain to
be investigated. The combined data support mutations in
STUB1 as a rare cause of ARCA and broadens the clinical
picture of the role of STUB1 mutations in human disease.
Disorders of protein ubiquitination and thus protein
turnover and homeostasis seem to be involved in both
ataxias and neurodegenerative diseases. For neurodege-
nerative diseases such as Alzheimer and Parkinson, rare
Mendelian forms have directly linked aberrations of the
ubiquitination-proteasome system with the disease process
[23-25]. In light of the range of mutations in various genes
associated with ARCAs, the molecular mechanisms for
similar disease are very complex and thus it is not surpris-
ing that the clinical picture is diverse. CHIP has at least two
functions; as a co-chaperone for HSPs and other binding
partners, and as an ubiquitin ligase [9,26]. In some ARCAs,part of the mechanism may involve the interaction between
CHIP and ataxin-1 [11]. As CHIP has three domains with
distinct functions, differences in patient phenotype could
be related to the position of the mutation within the various
domains. Our Family 1 is one of three reported with a
mutation in the TPR domain. The patients reported by
Synofzik et al. [7] also harboured mutations in the TPR
domain, and the clinical report did not include hormonal
derangements, thus it is possible that mutations affecting
this domain do not predispose to hypogonadotrophic hypo-
gonadism. Furthermore, although 3/4 of our patients had
progressive disease, none of the patients showed progres-
sive and debilitating dementia or white matter changes on
MRI as reported in RNF216 related ataxia [2]. In contrast
to the findings of Synofzik et al. [7], none of our patients
had spasticity. Very interestingly, features of accelerated
ageing as observed in our Family 1, has not previously been
reported in other STUB-related ARCA patients, but has
been observed in CHIP knockout mice [15].
Our study documents at least two additional mechanisms
whereby STUB1 may contribute in the disease process.
Firstly, we show that the STUB1 mutations studied here
result in a loss-of-function of CHIP, most likely related to
























































Figure 6 Different E3 ubiquitin ligase activity is observed for various CHIP mutants. In vitro ubiquitination was assessed using CHIP-WT and
CHIP-mutant forms as E3 ligases and HSC70 recombinant protein as substrate for ubiquitination. Samples were analyzed by SDS-PAGE followed by
immunoblotting using HSC70- and CHIP-specific antibodies. A reaction with WT-CHIP and without ubiquitin was used as a negative control (CTL). Both
the levels of ubiquitination of HSC70 and auto-ubiquitination of CHIP itself was investigated using MBP-CHIP fusion protein (A) and tag-free (cleaved)
CHIP (B). The lower molecular weight CHIP-K144* deletion mutant were detected as a MBP fusion protein, but not as a tag-free mutant, presumably
due to reduced protein stability after removal of the MBP. The asterisks indicate CHIP forms mostly observed for CHIP-T246M and possibly representing
protein dimers.
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N65S protein compared to normal fibroblasts (CHIP-WT),
while protein corresponding to the CHIP-K144* allele is
completely absent. This is probably explained by the in vivo
cell machinery detecting and marking most of the aberrant
CHIP-proteins for degradation, since also low levels of
mutant transcript was observed in our RNA analyses. We
believe that reduced protein level, alone, is the mechanism
for disease development in the compound heterozygous
patient carrying the CHIP-K144* and the CHIP-E28K
variant. Secondly, the causal mutation in Family 1 (CHIP-
N65S) is located in the TPR domain of the protein, affecting
a residue previously reported involved in substrate binding
[21]. Based on the reduced ability of the CHIP-N65S mutantto ubiquitinate HSC70, reduced substrate affinity is thought
to be a contributing factor to disease in this family, in
addition to reduced protein level, as described above.
Whether protein instability also contributes to the loss-of-
function disease mechanism of the previously reported
CHIP variants, is unknown. This possibility is supported by
the phenotypic similarity reported between ARCA patients
and the KO-mouse (CHIP−/−) model [15]. Mice lacking
CHIP exhibit a deregulation of the protein quality control.
Moreover, CHIP−/− mice have a number of derangements
including cardiomyopathy and accelerated aging. We did
not find clinical evidence for cardiomyopathy in our pa-
tients, but all three siblings in Family 1 looked considerably
older than their chronological age, and two had audiological
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adults. Symptoms of accelerated ageing have not been
reported in ARCAs before and could indicate difference in
severity of the reported mutations, however these are only
speculations. An age-related decrease in proteasome activity,
but not specifically in CHIP activity, has been described
[27]. The proteasome may be regarded as the downstream
effector of the ubiquitin-proteasome system. Decreased
activity may weaken cellular capacity to remove oxidatively
modified proteins and thus promote the development of
ageing. In addition, our index patient has diabetes type 1
and unexplained alopecia and his brother ulcerative colitis
and uveitis, all of unknown etiology, but commonly
regarded as autoimmune diseases. Whether or not this is
due to chance or represents a causal link between STUB1
mutation and dysregulation of ubiquitination in these
diseases, remain to be seen. However, CHIP negatively
modulates regulatory T cells in response to stress. CHIP
cooperates with HSP70 [15,28] in ubiquitinating Foxp3, a
central regulator of T cells, providing a glimpse of a theoret-
ical mechanism for such a link.
Conclusions
Taken together, our results demonstrate that STUB1
mutations can cause ARCA by novel mechanisms such as
protein instability and impaired substrate binding, leading to
ataxia and hypogonadism. Additional features like acceler-
ated ageing is possibly related to certain STUB1 mutations,
as seen in our Family 1, further refining the clinical
spectrum of disease.
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